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Parkin Protects against the Toxicity Associated
with Mutant -Synuclein: Proteasome Dysfunction
Selectively Affects Catecholaminergic Neurons
C-terminal hydrolase (UCHL1, OMIM 191342) has been
described (Farrer et al., 2000; Leroy et al., 1998), al-
though pathogenicity of this mutation has not been fully
established. However, polymorphic variability in UCHL1
has been associated with altered risk for development
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tosomal dominant pedigrees (OMIM 601508, Kruger etJacksonville, Florida 32224
al., 1998; Polymeropoulos et al., 1997). Several pieces2 Department of Pharmacology
of evidence suggest that -synuclein mutations and pro-Loyola University Medical Center
teasome function may be related. Whether -synucleinMaywood, Illinois 60153
turnover is regulated by proteasome function is contro-3 Laboratory of Neurogenetics
versial, with both positive (Bennett et al., 1999; TofarisNational Institute on Aging
et al., 2001) and negative (Ancolio et al., 2000; PaxinouBethesda, Maryland 20892
et al., 2001) results reported. Forced overexpression of
-synuclein, especially mutant forms, sensitize PC12
(Stefanis et al., 2001; Tanaka et al., 2001), NT2, and SK-Summary
N-MC (Lee et al., 2001b) neuroblastoma cell lines to
toxicity induced by the proteasome inhibitor lactacystin.One hypothesis for the etiology of Parkinson’s disease
The mechanism by which this occurs is not clear, but(PD) is that subsets of neurons are vulnerable to a
overexpression of mutant -synuclein produces an inhi-failure in proteasome-mediated protein turnover. Here
bition of proteasome-associated proteolytic activities.we show that overexpression of mutant -synuclein
The A30P mutant -synuclein inhibits the postacidicincreases sensitivity to proteasome inhibitors by de-
proteasome activity by 25% and the trypsin-like andcreasing proteasome function. Overexpression of par-
chymotrypsin-like activities by slightly smaller amounts,kin decreases sensitivity to proteasome inhibitors in
with wild-type -synuclein having a much smaller effecta manner dependent on parkin’s ubiquitin-protein E3
(Tanaka et al., 2001). The A53T mutant form of -synu-ligase activity, and antisense knockdown of parkin in-
clein also inhibits the chymotrypsin-like activity of thecreases sensitivity to proteasome inhibitors. Mutant
proteasome (Stefanis et al., 2001). Finally, it has been-synuclein also causes selective toxicity to catechol-
reported that an O-glycosylated form of-synuclein foundaminergic neurons in primary midbrain cultures, an
in human brain is ubiquitinated by parkin (Shimura et al.,effect that can be mimicked by the application of pro-
2001), raising the possibility that loss of parkin functionteasome inhibitors. Parkin is capable of rescuing the
might result in -synuclein accumulation. -synuclein-toxic effects of mutant-synuclein or proteasome inhibi-
positive Lewy bodies have been noted in a case of Par-tion in these cells. Therefore, parkin and -synuclein are
kin-related PD (Farrer et al., 2001).linked by common effects on a pathway associated with
Overall, the above studies suggest that proteasomeselective cell death in catecholaminergic neurons.
inhibition might be a common link between the different
genetic triggers of PD. Furthermore, there is evidenceIntroduction
that proteasome function is impaired in sporadic PD
(McNaught and Jenner, 2001). However, the hypothesis
The identification of genes linked to familial forms of
that proteasome dysfunction is an explanation for PD
Parkinson’s disease (PD) provides an important tool for remains conjecture. For example, as cell loss in PD is
modeling the pathways leading to neurodegeneration not uniform, any attempt to link proteasome function
in this disorder. To date, eight linkages have been re- to disease should account for selective vulnerability of
ported, with three genes identified as causal, or proba- specific subgroups of neurons. The selective vulnerabil-
bly causal, in different families. Two of these encode ity of different neuronal types to cell death or formation
proteins whose function is related to ubiquitin-depen- of the pathological hallmarks of the disease is complex
dent protein degradation through the proteasome (for (reviewed in Braak and Braak, 2000), but it is clear that
review, see Hershko and Ciechanover, 1998). Parkin functional loss of dopaminergic neurons in the substan-
(OMIM 600116) is an E2-dependent E3 protein-ubiquitin tia nigra (SN) pars compacta is important. The move-
ligase (Shimura et al., 2000; Zhang et al., 2000), and ment-related symptoms of PD patients are related to
mutations in this gene are generally associated with dopaminergic cell loss, and loss of these cells not only
recessive early onset parkinsonism (Kitada et al., 1998). precedes symptom development, it is also progressive
Parkin mutations reported to date appear to be loss- throughout the course of the disease (Pakkenberg et
of-function mutations reducing the ability of parkin to al., 1991).
regulate degradation of substrate removal (Shimura et In the present study we have explored the relationship
al., 2000; Zhang et al., 2000). One mutation in ubiquitin- between overexpression of -synuclein and parkin with
toxicity associated with proteasome inhibition. We have
also used primary cell cultures to distinguish effects on4 Correspondence: cookson@mail.nih.gov
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Figure 1. Effects of Proteasome Inhibitors on Cell Viability in M17 Cells Overexpressing -Synuclein
(A and B) Stable clonal cell lines overexpressing-synuclein were established and expression screened using Western blotting using monoclonal
antibody 42. Untransfected cells (lane 2) or cells transfected with vector alone (lane 3) show moderate expression of -synuclein compared
to cells overexpressing wild-type (lane 4), A30P (lane 5), or A53T synuclein (lane 6). Human cerebral cortex extract was used as a positive
control (lane 1). A reprobe of the same blot using -actin is shown below to demonstrate similarity of loading across the lanes. Quantitation
of -synuclein expression is shown in (B) and is expressed as a ratio of the major synuclein band to -actin (n  4 serial passages of the
cells, error bars represent the SEM).
(C and D) Overexpression of -synuclein produces increased sensitivity to the proteasome inhibitor MG132 (C) or lactacystin (D). Cells were
exposed to either inhibitor for 24 hr, after which cell viability was estimated using the MTT assay (see Experimental Procedures). Cell lines
included untransfected cells (open squares) or cells transfected with empty vector (open circles), WT (open triangles), A30P (closed squares),
or A53T (closed circles) -synuclein. Results are expressed as a percentage of untreated cells for each clonal line (n  8, each curve is
representative of three or more experiments). Similar increased sensitivity to proteasome inhibition was seen in a second set of clonal lines.
Statistical significance was estimated using two-way ANOVA using cell lines and concentration of inhibitors as independent variables. **p 
0.001 for differences between cell lines, both inhibitors having a significant effect on viability at p  0.001. Representative data from one of
three experiments.
tyrosine hydroxylase (TH)-positive neurons compared to Results
TH-negative neurons. We show that parkin and mutant
-synuclein have opposite effects on neuronal cell death Overexpression of -Synuclein and Sensitivity
to Proteasome Inhibitorsassociated with impaired proteasome function and that
parkin is capable of reducing toxicity associated with We used human M17 neuroblastoma cells to explore
the relationship between mutant forms of -synuclein-synuclein overexpression. We also show that knock-
down of parkin increases the sensitivity of cells to pro- and proteasome function. Cell lines stably overexpress-
ing wild-type or either of the two mutants expressedteasome inhibition, suggesting that loss-of-function mu-
tations in parkin would cause cell death by the same about a 5-fold increased level of -synuclein compared
with untransfected cells (Figure 1A). Although the ex-mechanism as gain-of-function -synuclein mutations.
Furthermore, the effects of either mutant -synuclein or pression levels are high compared with untransfected
cells,-synuclein protein expression in human brain wasproteasome inhibition are both selective for TH-positive
neurons. 9-fold higher than untransfected M17 cells and approxi-
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Figure 2. Measurements of Proteasome Ac-
tivity in Living Cells
(A and B) Overexpression of mutant
-synuclein decreases proteasome activity.
Stable cell lines (as in Figure 1) were tran-
siently transfected with the GFPu construct
(see text for description of the construct).
These included vector (lanes 1–3), cells ex-
pressing wild-type -synuclein (4–6), A30P
(7–9), or A53T (10–12) mutant -synuclein.
Protein extracts were blotted for GFP-CL1
peptide using anti-GFP (top panel) then re-
probed sequentially for -synuclein (middle
panel) and -actin (bottom panel). A semi-
quantitative analysis was performed by den-
sitometry, correcting GFP-CL1 levels for
-actin. Each bar is the mean of the samples
shown in (A) plus a duplicate set (hence n 
6), and error bars indicate the SEM. Both mu-
tant forms of synuclein increased the amount
of reporter construct, which was significant
between cell lines at p  0.001 by ANOVA.
(C–E) Additive effects of mutant -synuclein
expression and proteasome inhibition. (C)
Vector (lanes 1–6) or A30P mutant -synu-
clein cell lines (7–12) were transfected with
GFPu then, after 48 hr, treated with 5 M lac-
tacystin for 6 hr. Protein extracts were blotted
for GFP, -synuclein, and -actin (top, mid-
dle, and bottom panels, respectively) and
semiquantitative analysis for GFP immunore-
activity (D) or -synuclein (E) normalized to
-actin for the same gel, bars are the mean
of the samples shown in (C) plus a duplicate
set (hence n  6), and error bars indicate the
SEM. Similar results were obtained in dupli-
cate experiments.
mately 30% higher than the highest expressing clone where cell viability was decreased to 68%  5%. Cells
transfected with either of the mutant forms of -synu-of A30P cells. We also generated a second set of lines
with similar levels of expression (data not shown). clein were much more sensitive to MG132. The largest
effect was seen in cells overexpressing A30P where cellWe examined the sensitivity of these cell lines to toxic-
ity induced by proteasome inhibition (Figure 1C). Expo- viability was 30% 0.4% at 10 M MG132. Overexpres-
sion of A53T -synuclein decreased cell viability tosure to 10 M MG132 caused cell viability to be de-
creased to 74%  1% of untreated for untransfected 50%  1% at the same concentration. Similar results
were seen with a second set of clones. For example,cells and 76%  0.8% for vector cells (n  8). For wild-
type-synuclein transfectants, a small increase in sensi- using two independent A30P-expressing clonal lines,
cell viability after exposure to 10 M MG132 was de-tivity was noted at the highest tested concentration,
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Figure 3. Effects of Proteasome Inhibitors on Cell Viability in M17 Cells Overexpressing Parkin
(A) Parkin protein was measured by Western blotting using a C-terminal antibody to human parkin in clonal lines transfected with vector (lane
1) or expression vector for human parkin (lane 2). Full-length parkin runs at 50 kDa (arrow) although a C-terminal fragment (42 kDa) is also
noted in the overexpressing cell line (asterisk). Equal loading was demonstrated by reprobing the same blot with -actin.
(B and C) Overexpression of parkin protects cells against the toxic effects of the proteasome inhibitor MG132 (B) or lactacystin (C). Cells
stably transfected with parkin (open symbols) or vector (closed symbols) were exposed to inhibitors for 24 hr and cell viability assessed as
in Figure 4. Statistical significance was estimated using two-way ANOVA using cell lines and concentration of inhibitors as independent
variables. *p  0.05; **p  0.001 for differences between cell lines, both inhibitors having a significant effect on viability at p  0.001. Similar
protective effects of parkin overexpression were seen in two independent experiments (each n  8).
(D) In an independent set of experiments, cells overexpressing mutant Parkin (R42P) were not protected from exposure to 10 M (filled bars)
or 25 M (striped bars) lactacystin. (n  8, representative of two experiments.)
(E) Cells were transfected with vector, the E3 ligase E6-AP, Parkin alone, or Parkin in the presence of a dominant-negative inhibitor of the E2
enzyme UbCH7 and exposed to 10 M lactacystin. Cell death was quantified as above (n  8) and expressed as a percentage of MTT
conversion for transfected cells that had not been exposed to lactacystin. The differences between vector and parkin transfected cells were
significant.
(F) Antisense knockdown of Parkin increases steady-state levels of heterologous substrates. M17 cells stably transfected with wild-type Parkin
(lanes 3 and 4) or an antisense parkin construct (lanes 5 and 6) were transiently transfected with GFPu reporter as above (upper panel) or
transfected and then treated with MG132 (middle panel). Vector-only cells were included as controls (lanes 1 and 2, duplicate clonal lines).
Parallel samples were blotted for parkin (lower panel) to demonstrate the level of overexpression and the effect of antisense knockdown.
GFP-CL1 levels were unaffected by expression of parkin (similar effects were seen in two independent experiments), although antisense
parkin cell lines did show an accumulation of GFP-CL1.
(G) MTT assays in the same cell lines show that cells transfected with antisense parkin (open circles) are more sensitive to MG132 toxicity
compared to vector-only lines (closed circles) or cells transfected with WT parkin (closed triangles). Results are expressed as a percentage
of untreated cells for each clonal line (n  8, each curve is representative of two or more experiments).
Proteasome Failure and Parkinson’s Disease
1011
Figure 4. Characterization of -Synuclein
and -Synuclein Expression in Primary Post-
natal Midbrain Neurons
Primary neuronal cultures from postnatal
mouse midbrain were stained with polyclonal
antibodies to tyrosine hydroxylase (TH, green
in [A]–[D]) and monoclonal antibodies to
-synuclein ([A] and [B] shows higher mag-
nification) or synaptophysin ([C], higher mag-
nification shown in [D]). The monoclonal
antibody clone 42 (A and B) recognizes en-
dogenous (mouse) -synuclein. Staining for
-synuclein was performed using a poly-
clonal antibody (green in [E] and [F]) in combi-
nation with monoclonal anti-TH (red in [E] and
[F]). All three proteins were expressed in both
TH-positive (arrows) and TH-negative cells
with similar patterns. Higher magnification of
TH-positive cells (B, D, and F) demonstrated
localization at the cell membrane, reminis-
cent of synaptic structures (arrowheads). All
images were captured using a confocal mi-
croscope, and merged images of both chan-
nels are shown, yellow indicating overlap be-
tween the green and red channels. Scale bars
represent 50 m.
creased to 27%  1% in one clone and 30%  0.4% We next examined the mechanism by which mutant
-synuclein increases cellular sensitivity to proteasomein the second. Consistent results were also obtained for
two each of A53T and wild-type-synuclein clones (data inhibitors. We measured net proteasomal activity in liv-
ing cells using the GFPu reporter construct (Bence etnot shown). The differences between different clonal
cell lines were significant (p  0.0001) using two-way al., 2001). When transfected into cells, the CL1 peptide
(Gilon et al., 1998) sequence fused to GFP leads to rapidANOVA, as was the effect of MG132 across all cell lines
(p  0.0001). We also exposed cells to the structurally destruction of the protein, and in control cell lines we
found only small amounts of GFP-CL1 peptide (Figureunrelated inhibitor, lactacystin (Figure 1D). Lactacystin
required concentrations of up to 25 M to produce loss 2). The amount of reporter construct accumulation in
cells transfected with wild-type -synuclein was similarof cell viability to 70% (Figure 1D). Increased toxicity
was noted in cell lines expressing either A30P or A53T to that in vector-transfected cells but much higher in
cells expressing A30P or A53T mutants (Figures 2A and-synuclein. A small effect of wild-type -synuclein was
also seen. The differences between different clonal cell 2B). The differences in amounts of GFP-CL1 between
the cell lines were statistically significant (p  0.01 bylines were significant (p  0.004), as was the effect of
lactacystin (p0.0001). Similar results were seen in exper- ANOVA). We also treated vector- or A30P-transfected cells
with 5 M lactacystin for 5 hr, which increased steady-iments using a second set of clonal cell lines. Results
presented here using MTT conversion are similar to pre- state levels of the GFP-CL1 fusion protein. This effect
was enhanced in the presence of A30P mutant -synu-vious reports using Trypan blue dye exclusion as a mea-
sure of cell death (Tanaka et al., 2001). To address the clein (Figure 2D). Therefore, mutant -synuclein inhibits
proteasome function in a manner that is additive to thepossibility that such effects might be due to inhibition
of other proteases, we exposed cells to the cell-soluble effect of pharmacological inhibition of the proteasome.
There was no effect of lactacystin on steady-state -synu-calpain inhibitor E64d. This compound was without ef-
fect on cell viability up to 100 M, which approached clein levels in experiments where an increased GFP-
CL1 reporter protein demonstrated unequivocally thatthe limit of solubility (data not shown).
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Figure 5. Overexpression of -Synuclein in Primary Neurons
(A and B) Midbrain or hippocampal neurons were transduced with human -synuclein (WT or A53T) and protein extracts (10 g/lane) blotted
with (A) either monoclonal 42 (recognizes rodent and human -synuclein) or (B) LB509 (human -synuclein only). Similar levels of expression
were obtained with each of the viral constructs. Untransfected cells (UT) and cells transduced with a LacZ construct were used as controls.
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there was proteasome inhibition (Figure 2E). Given the cell was reduced, as occurs in ARJP. To model this
effect, we generated cell lines with an antisense con-possible inhibitory effect of -synuclein on -synuclein
toxicity (Hashimoto et al., 2001), we also examined struct that had lower steady-state levels of parkin pro-
tein. This antisense knockdown of parkin does increase-synuclein expression in the same cell extracts. We
were unable to detect -synuclein protein in either basal GFPu levels within the cell, and MG132 has an additive
effect (Figure 3F). This suggests that loss of parkin activ-conditions or after proteasome inhibition, although the
antibodies used did detect expression of this protein in ity increases the level of heterologous substrates, pre-
sumably due to increased levels of parkin substrateshuman brain (data not shown) and in primary mouse
cultures (see below). competing for ubiquitination and/or proteasome-medi-
ated degradation. Proteasome inhibitors are more toxic
in cell lines transfected with an antisense parkin con-Manipulation of Parkin Expression Levels
struct (Figure 3G).and Sensitivity to Proteasome Inhibitors
The above data demonstrate that the overexpression of
mutant -synuclein results in an increased sensitivity of Mutant -Synuclein Triggers Selective Cell Death
in Primary Neuronal Culturecells to loss of viability induced by proteasome inhibi-
tion. We examined what effect increased parkin activity Primary neuronal cultures from the midbrain of postnatal
mice (Mena et al., 1997) were used to examine the effectsmight have on the same parameters. Stable cell lines
transfected with the parkin cDNA had substantially in- of -synuclein overexpression and proteasome inhibi-
tion on different neuronal groups. These cultures arecreased parkin protein expression (Figure 3A). Over-
expression of parkin partially rescued cells from the predominantly from the nigral area and have a higher
proportion of TH-positive catecholaminergic neuronstoxic effects of MG132 (Figure 3B) or lactacystin (Figure
3C), with cell viability being 10%–20% higher in the par- than commonly used embryonic mesencephalic neuron
preparations, with TH-positive cells representing aboutkin cell lines compared to controls at all doses of either
compound. This effect was statistically robust (p0.001 20%–30% of the total neuronal population. The TH anti-
bodies we used in these experiments recognized anfor MG132, and p  0.004 for lactacystin).
Further experiments confirmed that the observed res- appropriately sized band in extracts from whole mouse
brain or from midbrain cultures but not in hippocampalcue of parkin is dependent on its E3 ligase activity. A
mutant form of parkin associated with loss of E3 ligase cultures (data not shown). We characterized the expres-
sion of (mouse) - and -synuclein in these cells (Figureactivity (R42P) was not able to rescue cells in an inde-
pendent set of experiments (Figure 3D). Again, the differ- 4). Both TH-positive and TH-negative neurons expressed
-synuclein (Figures 4A and 4B) at the cell surface in aences between wild-type parkin and R42P parkin were
statistically significant (p  0.001 for differences be- punctate pattern reminiscent of synaptic proteins such
as synaptophysin (Figures 4C and 4D), similar to hippo-tween wild-type parkin and either vector alone or R42P).
Coexpression of a dominant-negative E2 enzyme (UbCH7) campal neurons (Murphy et al., 2000). In addition, we
also noted -synuclein immunoreactivity in the cyto-also ameliorated the protective effect of parkin (Figure
3E). We also examined the effects of overexpression of plasm. This was not limited to either TH-positive or TH-
negative cells but was seen in many midbrain neurons.a second E3 ligase, E6AP, which was not protective
in these cells (Figure 3E). Experiments using the GFPu Expression of -synuclein (Figures 4E and 4F) was also
synaptic and seen in both cell populations at similarconstruct demonstrated that there was no alteration in
the amount of GFP-CL1 in the cells when transfected levels.
We next transduced primary midbrain cultures withwith parkin, either under basal conditions or after MG132
treatment (Figure 3F), although MG132 did increase wild-type or mutant -synuclein and monitored expres-
sion by Western blotting or immunocytochemistry. TwoGFP-CL1 levels in this experiment as in the experiments
shown in Figure 2 . Parkin does not, therefore, act as monoclonal antibodies, clone 42 and LB509, were used
to distinguish overexpressed human -synuclein froman E3 ligase for this artificial proteasome reporter (see
Discussion). However, the above experiments do not endogenous mouse -synuclein, respectively. Trans-
duction with wild-type or mutant -synuclein producedaddress what would occur if parkin activity within the
Left-hand panels show controls using brain lysates from mouse (mo) or human (hu) cerebral cortex. Blotting using monoclonal antibody 42
yielded a major band at 19 kDa (arrow) plus a smaller degradation product with an apparent molecular weight of 16–17 kDa (arrowhead): this
smaller product was not seen with LB509.
(C–K) Expression of human -synuclein in catecholaminergic neurons. Primary midbrain catecholaminergic neurons (TH-positive, green) were
transduced at multiplicities of infection (MOIs) of 5–10 with HSV1 expressing lacZ (C, D, and E) as a negative control or -synuclein (WT,
[F–H]; A53T, [I–K]). Transduction was demonstrated using a human specific monoclonal antibody LB509 (red), and more than 95% of cells
were LB509 positive. Merged images are shown on the right of each set of photomicrographs. Scale bar in (K) represents 50 m and applies
to all panels. Representative data is shown from one of four experiments.
(L–M) Overexpression of mutant -synuclein in primary midbrain neurons is associated with selective cell death of TH-positive cells. Cells
were transduced with either LacZ (negative control), WT, or mutant (A53T) -synuclein and cell numbers estimated by counting using TH and
MAP2 staining. Although there was a significant reduction in TH-positive cell numbers (L), TH-negative cells in the midbrain (M) and hippocampal
cells (N) were not affected. Each open circle is the average cell counts from one experiment with six fields counted in each of three cultures
(hence n 18): closed circles represent the mean from each of three experiments, with error bars representing the SEM between experiments.




similar levels of overexpression (Figures 5A and 5B). To Parkin Rescues the Toxicity of Mutant
-Synuclein in Primary Neuronsconfirm that TH-positive neurons in midbrain cultures
We reasoned that as parkin protected cells against pro-were transduced, cells were costained for TH and hu-
teasome inhibition and mutant -synuclein overexpres-man -synuclein using LB509 (Figures 5C–5K). We esti-
sion inhibited the proteasome then parkin might be pro-mated that after transduction at a multiplicity of infection
tective against toxicity associated with overexpression(MOI) of 10, more than 95% of TH-positive neurons ex-
of mutant -synuclein. We repeated the experimentspressed human -synuclein. TH-negative neurons were
using A53T -synuclein and coexpressed either lacZ astransduced at similarly high rates, showing almost 100%
a control or parkin (Figures 7A and 7B). Cotransductioninfectivity at MOIs of 5–10 (data not shown). Overexpres-
of parkin restored the number of counted neurons backsion in this acute model does not result in the formation
to levels similar to cultures treated with lacZ alone. Usingof microscopically visible -synuclein aggregates (Fig-
one-way ANOVA with post-hoc tests as above, the lossure 5J).
of TH-positive neurons was significantly different (p Cell counts were performed to assess whether the
0.05) from controls and from cultures treated with parkinoverexpressed -synuclein induced any toxicity in TH-
and -synuclein (p  0.05), but the difference betweenpositive neurons. In each experiment, we counted six
cotransduced cultures and control cells was not signifi-fields in each of three cultures. We also repeated the
cant. Similarly to experiments in cell lines, Parkin waswhole series three times with independent purifications
able to rescue to selective toxicity of MG132 to primaryof viral particles, and the data presented (Figure 5L)
cells (Figures 7C and 7D).shows the interexperiment variation. We were able to
demonstrate a clear toxic effect of A53T -synuclein in
DiscussionTH-positive cells. We were not able to demonstrate an
effect with wild-type -synuclein under these condi-
In the current study, we have examined manipulation oftions. TH-negative midbrain neurons (Figure 5M) or hip-
two genes that show association with familial PD onpocampal neurons (Figure 5N) were unaffected by the
cellular sensitivity to proteasome inhibition and havepresence of A53T -synuclein.
examined aspects of neuronal selectivity. There was an
increased sensitivity of cells overexpressing-synuclein
to proteasome inhibition, similar to previous reports (LeeTH-Positive Neurons Are Selectively Vulnerable
et al., 2001b; Tanaka et al., 2001). Mutant -synucleinto Proteasome Inhibition
also sensitizes cells to other insults (Junn and Moura-We next examined whether proteasome inhibition was
dian, 2002; Ko et al., 2000; Lee et al., 2001b; Ostrerova-sufficient to produce selective neuronal cell loss in the
Golts et al., 2000; Zhou et al., 2000), but we and otherssame manner as -synuclein overexpression. The num-
(Stefanis et al., 2001; Tanaka et al., 2001) have demon-bers of TH-positive neurons in MG132 were decreased
strated that one effect of mutant-synuclein is to reducecompared to controls, with remaining cells often show-
the net proteasomal activity in living cells. Therefore,ing shrinkage of cell bodies and retraction of neuritic
proteasome inhibition is likely to make a significant con-
processes (Figures 6A and 6B). Previous reports of cell
tribution to cell death induced by mutant -synuclein.
death induced by proteasome inhibitors in the presence
The inhibition of proteasome function by mutant -synu-
of mutant -synuclein have given contradictory results
clein may be a direct inhibition of proteasome activity,
on the mode of cell death, finding evidence for apoptosis as-synuclein can bind to one of the regulatory subunits
(Tanaka et al., 2001) or autophagy (Stefanis et al., 2001). of the proteasome (Ghee et al., 2000) or the presence
In our cultures exposed to proteasome inhibitors, coun- of large amounts of misfolded or unfolded proteins, such
terstaining nuclei with Hoechst 33342 revealed that even as mutant -synuclein, might inhibit the ubiquitin-pro-
in damaged cells the nuclei remained intact, unlike apo- teasome pathway indirectly (Bence et al., 2001).
ptosis. The numbers of TH-positive cells were signifi- Overexpression of parkin protected against toxicity
cantly reduced at higher concentrations of lactacystin associated with reduced proteasome function. The lack
or MG132 (Figures 6C and 6E), while the number of TH- of effect of the recessive R42P parkin mutation, which
negative neurons was unaffected (Figures 6D and 6F). lacks ubiquitination activity (Shimura et al., 2001), dem-
Using one-way ANOVA with Student-Newman-Kuells onstrates that mutant forms of parkin are unable to pro-
post-hoc test to evaluate the effects of proteasome inhi- tect dopaminergic neurons against proteasome failure.
bition on numbers of TH-positive cells remaining, MG132 Therefore, both genes implicated in familial PD alter
had a significant (p  0.05) effect at both 1 and 5 M, the ability of neurons to tolerate reduced proteasome
whereas the effect of lactacystin was significant only at activity. We have shown that the E3 ligase activity of
10 M. We also examined the effects of proteasome Parkin is required for protection, as a dominant-negative
inhibitors on A53T-synuclein-infected primary cultures E2 mutant could ameliorate this effect. Experiments us-
(Figures 6G and 6H). The two treatments had an additive ing the GFPu reporter show that Parkin does not increase
effect (p  0.01 by ANOVA for all groups), although the net proteasome activity, consistent with the role of this
loss of TH-positive cells was not complete after 24 hr, E3 ligase in controlling entry of target proteins into the
the time point used for this study. We examined cells proteasome via ubiquitination, and does not alter the
transduced with A53T synuclein and treated with MG132 steady-state levels of -synuclein. Parkin is also protec-
after staining with Hoechst 33342 (as in Figures 6A and tive in some other models of cell death, such as ER
6B) and again did not find evidence for apoptosis (data stress, but is not protective against all insults, including
staurosporine (Imai et al., 2000). We suggest that parkinnot shown).
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Figure 6. Catecholaminergic Neurons Are
Preferentially Susceptible to Proteasome In-
hibition in Primary Culture
(A and B) Primary midbrain cultures were left
untreated (A) or exposed to 10 M MG132
for 24 hr (B) and stained for MAP2 (red), TH
(green), and Hoechst 33342 (blue) to demon-
strate nuclear morphology. Exposure to the
proteasome inhibitor caused TH-positive
cells to become shrunken and retract pro-
cesses, but nuclei remained intact (inset in [B]).
(C–F). Cell counts after exposure to MG132 (C
and D) or lactacystin (E and F). Both inhibitors
substantially affected the TH-positive neu-
ronal population (C,E), whereas TH-negative/
MAP2-positive neurons (D and F) were unaf-
fected. Data are shown as cell counts from
six randomly selected microscope fields in
each of three replicate cultures (hence n 
18) and is representative of two to four inde-
pendent experiments with different batches
of primary cells. Statistical significance was
assessed using one-way ANOVA with Stu-
dent-Neuman-Kuells post-hoc tests between
each group (*p  0.05).
(G and H) Additive effect of -synuclein over-
expression and proteasome inhibition. Pri-
mary cells as above were transduced with
mutant -synuclein as in Figure 5 for 24 hr
then exposed to MG132 for a further 24 hr.
Cell counts revealed a loss of TH-positive
neurons (G) after either treatment but an addi-
tive effect of both treatments together (*p 
0.05 by one-way ANOVA with Student-New-
man-Kuells post-hoc test).
protects against the accumulation of its specific protein deletions are predicted to reduce enzyme activity to
extremely low levels and hence an antisense experimenttarget(s). Accumulation of these downstream target pro-
teins may also be promoted through ER stress due to is closer to this disease model than overexpression. In
this experimental setting, there is a clear accumulationa decreased ability of the cells for proper protein folding.
The nature of the targets for parkin’s E3 ligase activity of heterologous substrates, as evidenced by accumula-
tion of the GFP-CL1 reporter peptide, suggesting thatis still under investigation, although several candidates
have been reported (Chung et al., 2001; Imai et al., 2001; loss-of-function alleles would decrease the ability of
nigral neurons to regulate levels of proteasome sub-Shimura et al., 2001; Zhang et al., 2000). We also show
that knockdown of parkin using a stable antisense con- strates. It has been shown recently that proteasome
inhibition in vivo damages nigral neurons (McNaught etstruct increased sensitivity of cells to proteasome inhibi-
tion. This is, in many ways, a better model for loss-of- al., 2002). Our results predict that loss of parkin function
would have the same effect.function mutations than overexpression of the wild-type
protein. In ARJP, for example, homozygous large-scale Both overexpression of mutant -synuclein and pro-
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Figure 7. Parkin Rescues Toxicity Associ-
ated with Mutant -Synuclein or Proteasome
Inhibition in Primary Midbrain Cells
Primary midbrain neurons were transduced
with both mutant -synuclein and wild-type
human parkin. Where either virus was absent
(), LacZ was substituted to keep the total
number of viral particles similar. There was
a significant reduction in the number of TH-
positive neurons (A), which was ameliorated
by coexpressing parkin. No effect on TH-neg-
ative cells was noted (B). Data are shown as
cell counts from six randomly selected micro-
scope fields in each of three replicate cultures
(hence n  18), and statistical significance
was assessed using one-way ANOVA with
Student-Neuman-Kuells post-hoc tests be-
tween each group (*p  0.05; ns, not signifi-
cant). Similar protective effects were noted
using exposure to MG132 to induce toxicity
(C and D) where selective toxicity to TH-posi-
tive cells was noted (C). The numbers of cell
counts and statistical tests are as in (A)
and (B).
teasome inhibition produce selective loss of TH-positive We did not find microscopically visible protein aggre-
gates, nor did we see the formation of higher molecularneurons. Therefore, proteasome inhibition is sufficient
to mimic the effects of mutant -synuclein. It is not the weight species of -synuclein as seen in some models
(Lee et al., 2001a). We believe that this is compatiblecase that all catecholaminergic neurons are severely
affected in PD, while all non-dopaminergic neurons are with the idea that protein aggregation to the extent of
formation of insoluble fibrillar species is not a requiredspared (Braak and Braak, 2000). Nonetheless, we have
shown that the SN contains a population of TH-positive step for -synuclein toxicity. Soluble protein complexes
appear to mediate the toxic effects of mutant -synu-cells that are particularly sensitive to both proteasome
inhibition and -synuclein overexpression. The higher clein in human dopaminergic cells (Xu et al., 2002). The
formation of protein aggregates is clearly relevant to thesensitivity of catecholaminergic neurons to damage in-
duced by overexpression of mutant -synuclein may human disease, as the formation of insoluble protein
deposits in the form of Lewy bodies occurs in survivingbe due to the ability of catecholamines to promote the
formation of protofibrillar forms of -synuclein (Conway neurons. Previous results using iron/dopamine-medi-
ated toxicity have shown that although formation of pro-et al., 2001). It has been suggested that -synuclein
protofibrils are a major toxic species of this protein, tein aggregates and toxicity can be seen under similar
conditions, these are dissociatable phenomena (Ostrer-and mutations in -synuclein also promote protofibril
formation (Conway et al., 2000). Recently, it has been ova-Golts et al., 2000). Proteasome inhibition might con-
ceivably affect the fibrillization properties of -synucleinshown that, in cultured human dopaminergic neurons,
dopamine is required for the toxic effects of mutant through the phenomenon of “molecular crowding” (Ellis,
2001). Two recent studies have demonstrated that in--synuclein, supporting this hypothesis (Xu et al., 2002).
We have not seen a protective effect of the same tyro- creasing the concentration of macromolecules in the
immediate surroundings of -synuclein increases itssine hydroxylase inhibitor (-methyl-para-tyrosine; AMPT)
in the stable cell lines we used in this study, but this is propensity to form protofibrillar and fibrillar species
(Shtilerman et al., 2002; Uversky et al., 2002). By inhib-confounded by a small toxic effect of AMPT alone in
our hands (M.R.C. and M.B., unpublished data). In our iting proteasome function, concentrations of many cyto-
solic proteins will increase, thereby inducing a molecularexperiments, mutant -synuclein is more toxic to TH-
positive cells than the wild-type protein. Overexpression crowding effect. Therefore, if formation of protofibrillar
forms of -synuclein is important for the toxicity of theof -synuclein in embryonic mesencephalic cultures
(Zhou et al., 2000) or human dopaminergic cells (Xu mutant forms, proteasome inhibitors are likely to accel-
erate this process, without having an effect on netet al., 2002) produces a similar effect. In some mouse
transgenic models, there is pathology associated with -synuclein protein concentrations. Protection by par-
kin of TH-positive neurons exposed to either mutanta substantial overexpression of wild-type -synuclein,
and there are reports of dopaminergic cell loss in some -synuclein or proteasome inhibition suggests that
these two stresses damage cells by similar mechanisms.(Masliah et al., 2000) but not all (Matsuoka et al., 2001;
Rathke-Hartlieb et al., 2001; VanDerPutten et al., 2000) In the results reported here, antisense-mediated knock-
down of parkin also increased levels of heterologousmodels. In a Drosophila model, loss of dopaminergic
neurons is also seen (Feany and Bender, 2000) with substrates, again potentially inducing accumulation of
several toxic proteins and inducing a crowding effect.mutant -synuclein having a more substantial effect
than wild-type. Our data are similar to viral-mediated The protective effect of parkin on loss of TH-positive
neurons mediated by mutant -synuclein demonstratesgene transfer experiments where mutant -synuclein
produces nigral cell loss (Kirik et al., 2002). that these two proteins have interrelated effects. The
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blocking (5% v/v goat serum plus 5% FBS in DPBS, 30 min), primaryabove data suggest that an increased sensitivity of cells
antibodies were applied overnight at 4C. These were a combinationto the toxic effects of proteasome inhibition link -synu-
of polyclonal antibody to TH (Chemicon, 1:200) and monoclonal anti-clein and parkin as well as providing an explanation
MAP2 (clone AP-20, Sigma) both at a dilution of 1:200. Secondary
for the selective loss of a subgroup of dopaminergic antibodies were goat anti-rabbit conjugated to Alexafluor488 (Mo-
neurons in PD. Whether proteasome inhibition will pro- lecular Probes) and goat anti-mouse conjugated to AlexaFluor 568.
For estimations of cell numbers, six random microscope fields (usingvide a full explanation for neuronal damage in PD is not
a 20	 objective) were counted in each of three sister cultures, forclear. There are several genes linked to familial PD that
a total of 18 fields per condition, counting all neuronal cells withinremain to be identified, and it will be critical to evaluate
each field. Each experiment was repeated two to four times withwhether manipulations of these products also produces
different batches of primary cells. For staining of -synuclein, mono-
increased sensitivity to proteasome inhibition. clonal anti-human -synuclein LB509 (Zymed) or monoclonal anti-
rodent -synuclein (clone 42, listed above) were used in the above
Experimental Procedures protocol at a dilution of 1:200. A polyclonal antibody to -synuclein
(Chemicon) was used at 1:500 in conjunction with monoclonal anti-
Human Neuroblastoma Cell Lines body to TH (also Chemicon, 1:200).
The production of stable cell lines overexpressing wild-type or mu-
tant -synuclein from parental BE (2)-M17 human dopaminergic Viral Transduction
neuroblastoma cells has been detailed elsewhere (Ostrerova-Golts
-synuclein or parkin cDNAs were cloned into pHSVPrpUC and
et al., 2000). Full-length parkin cDNA was cloned into the same packaged into recombinant viral particles using 5dl1.2 helper virus
vector and transfections performed as described previously (Ostre- and the 2-2 packaging cell line as described (Neve et al., 1997) and
rova-Golts et al., 2000). An antisense construct was made by placing purified using sucrose gradients. A control virus expressing LacZ
the first 100 bp of coding sequence for parkin into pCDNA3.1 in the (from pHSVlacZ, Coopersmith and Neve, 1999) was prepared at the
reverse orientation relative to the vector promoter. Stable clones same time. Recombinant viruses were titred on human neuro-
were prepared as above and screened for reduced parkin expres- blastoma cell lines. Primary cells were transduced with viral particles
sion. For the present study, clonal lines for both -synuclein and at a multiplicity of infection (MOI) of 10. In a small series of experi-
parkin were made by limiting dilution and were maintained on 500 ments, we extracted cultures grown in 6-well plates and blotted for
g mL1 G418. Stable clonal lines were screened for -synuclein
-synuclein as above.
expression by Western blotting using monoclonal antibody to
-synuclein (Clone 42, Transduction Labs). Cell lysates (10 g total
Statistical Analysesprotein per lane) were separated on 16% SDS-PAGE gels (Novex)
Differences in the responses of cell lines to proteasome inhibitorsand transferred to Immobilon membranes (Immobilon, Inc). A soluble
were evaluated using two-way analysis of variance (ANOVA) withextract of adult human cerebral cortex was used as a positive con-
cell line and concentration of each proteasome inhibitor as variables.trol. After probing with primary antibody (1:1000), blots were devel-
For primary cell counts, one-way ANOVA with Student-Neuman-oped with peroxidase-labeled secondary antibodies (Jackson Im-
Kuells post-hoc test was used to assess differences between treat-munochemicals) using enhanced chemiluminescence substrates
ments with proteasome inhibitors or with transduction with different(Amersham). Blots were reprobed with -actin (Sigma, clone AC15,
viral constructs. For each of these experiments, six fields were1:5000) to verify equal loading. Quantitation of -synuclein expres-
counted in each of three independent cultures, hence n  18. Insion was performed by capturing enhanced chemiluminescence us-
experiments comparing the toxicity associated with overexpressioning a CCD camera-based system (AlphaImager, Alpha Innotech
of -synuclein, we repeated this whole set of experiments threeCorp). Parkin expression was also monitored by Western blotting
times.using a rabbit polyclonal antibody to the C terminus of parkin (Cell
Signaling Technology, 1:2000 dilution). Cell viability was assessed
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